Elevated RDW is Associated with Increased Mortality Risk in COVID-19

Foy, Brody H.; Carlson, Jonathan C.; Reinertsen, Erik; Valls, Raimon Padros I.; López, Roger Pallarès; Palanques-Tost, Eric; Mow, Christopher; Westover, M. Brandon; Aguirre, Aaron D.; Higgins, John M.

doi:10.1101/2020.05.05.20091702

Cited by 21 publications

(21 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Topaz et al showed that higher RDW was a predictor of severe hospital complications in patients with influenza [20]. Foy et al showed a relation between elevated RDW (>14.5%) and mortality in COVID-19 patients [21]. One centre study showed that there was no difference in RBC and haemoglobin levels in COVID-19 patients compared to controls [22].…”

Section: Discussionmentioning

confidence: 99%

The role of haematological parameters in patients with COVID-19 and influenza virus infection

Kazancıoğlu

Baştuğ²,

Özbay

et al. 2020

Epidemiol. Infect.

View full text Add to dashboard Cite

SARS-CoV-2, the causative agent of coronavirus disease 19 (COVID-19), was identified in Wuhan, China. Since then, the novel coronavirus started to be compared to influenza. The haematological parameters and inflammatory indexes are associated with severe illness in COVID-19 patients. In this study, the laboratory data of 120 COVID-19 patients, 100 influenza patients and 61 healthy controls were evaluated. Lower lymphocytes, eosinophils, basophils, platelets and higher delta neutrophil index (DNI), neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) were found in COVID-19 and influenza groups compared to healthy controls. The eosinophils, lymphocytes and PLR made the highest contribution to differentiate COVID-19 patients from healthy controls (area under the curves (AUCs): 0.819, 0.817 and 0.716, respectively; P-value is <0.0001 for all). The NLR, the optimal cutoff value was 3.58, which resulted in a sensitivity of 30.8 and a specificity of 100 (AUC: 0.677, P < 0.0001). Higher leucocytes, neutrophils, DNI, NLR, PLR and lower lymphocytes, red blood cells, haemoglobin, haematocrit levels were found in severe patients at the end of treatment. Nonsevere patients showed an upward trend for lymphocytes, eosinophils and platelets, and a downward trend for neutrophils, DNI, NLR and PLR. However, there was an increasing trend for eosinophils, platelets and PLR in severe patients. In conclusion, NLR and PLR can be used as biomarkers to distinguish COVID-19 patients from healthy people and to predict the severity of COVID-19. The increasing value of PLR during follow-up may be more useful compared to NLR to predict the disease severity.

show abstract

Section: Discussionmentioning

confidence: 99%

The role of haematological parameters in patients with COVID-19 and influenza virus infection

Kazancıoğlu

Baştuğ²,

Özbay

et al. 2020

Epidemiol. Infect.

View full text Add to dashboard Cite

show abstract

“…It is interesting to mention here that the results of some additional COVID-19 clinical investigations, which could not be included in our analysis because they did not provide absolute RDW values, seem to be firmly aligned with these conclusions. Briefly, Foy et al [ 20 ] studied 1,198 COVID-19 patients and found that those with an increased RDW value at admission (i.e., >14.5%) had a 2.5-fold higher risk of in-hospital mortality compared to those with lower values (i.e., 22 vs. 9%; relative risk, 2.5; 95% CI 2.25–2.83). Moreover, an in-hospital increasing RDW was also associated with enhanced risk of death.…”

Section: Discussionmentioning

confidence: 99%

Red Blood Cell Distribution Is a Significant Predictor of Severe Illness in Coronavirus Disease 2019

2020

View full text Add to dashboard Cite

Introduction As red blood cell distribution width (RDW) significantly predicts clinical outcomes in patients with respiratory tract infections and in those with critical illnesses, we performed a critical analysis of the literature to explore the potential prognostic role of this laboratory parameter in coronavirus disease 2019 (COVID-19). Methods An electronic search was conducted in Medline, Scopus and Web of Science, using the keywords “coronavirus disease 2019” OR “COVID-19” AND “red blood cell distribution width” OR “RDW” in all fields, up to the present time, with no language restriction. Studies reporting the value of RDW-CV in COVID-19 patients with or without severe illness were included in a pooled analysis. Results The pooled analysis included 3 studies, totaling 11,445 COVID-19 patients' samples (2,654 with severe disease; 23.2%). In all investigations RDW-CV was higher in COVID-19 patients with severe illness than in those with mild disease, with differences between 0.30 and 0.70%. The pooled analysis, despite consistent heterogeneity ( I 2 : 88%), revealed that the absolute RDW-CV value was 0.69% higher (95% CI 0.40–0.98%; p < 0.001) in COVID-19 patients with severe illness compared to those with mild disease. Conclusion These results, along with data published in other studies, support the use of RDW for assessing the risk of unfavorable COVID-19 progression.

show abstract

“…It should be noted that one mediator for virus entry, the glucose regulated protein 78 (GRP78), derived from bone marrow cells [ 56 ], suggesting that this may presumably affecting the erythropoiesis process [ 56 ]. Additionally, increased RBC distribution width (RDW) reported as a potential marker of slower erythropoiesis and turnover, has been correlated with enhanced COVID-19 mortality [ 57 ]. In addition, as reported by Ehsani [ 58 ], there exist a similarity between the cytoplasmic tail of the SARS-CoV-2 virus spike glycoprotein and the hepcidin binding protein, potentially contributing to disorder of iron metabolism and homeostasis.…”

Section: Angiotensin-converting Enzyme Inhibitors (Aceis) or Angiotenmentioning

confidence: 99%

Kidney diseases and COVID-19 infection: causes and effect, supportive therapeutics and nutritional perspectives

Askari

Sanadgol

Azarnezhad

et al. 2021

Heliyon

View full text Add to dashboard Cite

Recently, the novel coronavirus disease 2019 , has attracted the attention of scientists where it has a high mortality rate among older adults and individuals suffering from chronic diseases, such as chronic kidney diseases (CKD). It is important to elucidate molecular mechanisms by which COVID-19 affects the kidneys and accordingly develop proper nutritional and pharmacological strategies. Although numerous studies have recently recommended several approaches for the management of COVID-19 in CKD, its impact on patients with renal diseases remains the biggest challenge worldwide. In this paper, we review the most recent evidence regarding causality, potential nutritional supplements, therapeutic options, and management of COVID-19 infection in vulnerable individuals and patients with CKD. To date, there is no effective treatment for COVID-19-induced kidney dysfunction, and current treatments are yet limited to anti-inflammatory (e.g. ibuprofen) and anti-viral medications (e.g. Remdesivir, and Chloroquine/Hydroxychloroquine) that may increase the chance of treatment. In conclusion, the knowledge about kidney damage in COVID-19 is very limited, and this review improves our ability to introduce novel approaches for future clinical trials for this contiguous disease.

show abstract

Elevated RDW is Associated with Increased Mortality Risk in COVID-19

Cited by 21 publications

References 18 publications

The role of haematological parameters in patients with COVID-19 and influenza virus infection

The role of haematological parameters in patients with COVID-19 and influenza virus infection

Red Blood Cell Distribution Is a Significant Predictor of Severe Illness in Coronavirus Disease 2019

Kidney diseases and COVID-19 infection: causes and effect, supportive therapeutics and nutritional perspectives

Contact Info

Product

Resources

About